February 10th 2023, Evotec, a biotech company, received an unsecured loan facility of € 150 million from the European Investment Bank (EIB). The funding will support Evotec’s research and development operations, contribute to equity, and financially support the building processes of the new J.POD biologics manufacturing facility on Evotec’s Campus Curie located in Toulouse, France. The new manufacturing facility will introduce cutting-edge biomanufacturing to the European Union and offer essential clinical and commercial manufacturing capabilities for biologics.
Our data-driven R&D Autobahn to Cures will deliver speed and innovation efficiency for accessible medicines of the future.
- Dr Werner Lanthaler, CEO of Evotec
Founded in 1993 in Germany, Evotec is committed to discovering and developing exceptionally potent treatments and making them accessible to patients worldwide. In pursuit of this objective, Evotec has established itself as a worldwide platform firm, utilizing its data-driven multimodal platform for both in-house and collaborative research. Evotec collaborates with all of the leading 20 pharmaceutical companies as well as hundreds of biotechnology businesses, educational institutions, and other healthcare entities as part of its partner network.
The French government, the Occitanie Region, Bpifrance, the Haute-Garonne prefecture, and Toulouse Métropole are providing up to €50 million in support of the development of J.POD in Toulouse, France (EU).
This EIB investment will also have a significant impact on activity in the Toulouse region, as it will help to finance a 12,000 square meter plant that will create more than 200 highly skilled jobs.
- Ambroise Fayolle, EIB Vice President
Evotec will invest the loan, which has a total value of up to €150 million, over a period of three years. Each installment will mature seven years after it is disbursed. The EIB funding will help Evotec extend its product line, which now encompasses over 90 active initiatives in over 30 companies around the world.
